No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Respiratory infections are a major driver of antimicrobial resistance (AMR), yet the role of patient-handled devices remains overlooked. Inhalers, used daily by millions with asthma and COPD, directly contact the respiratory tract and may serve as reservoirs for resistant pathogens. This study presents the first large-scale, multi-country surveillance of antibiotic resistance genes (ARGs) on inhaler surfaces, assessing reservoir potential, concordance with nasal carriage, and clinical risk factors.
A total of 6,890 inhaler surface swabs and paired nasal/throat swabs were collected from adults (≥18 years) with asthma or COPD in Thailand, Sri Lanka, Myanmar, Laos, and Indonesia. Samples were screened for 250 clinically relevant ARGs using a smart RT-qPCR array system. Self-reported data on inhaler cleaning, storage, and recent antibiotic use were also obtained.
ARG profiles on inhaler surfaces strongly mirrored those in paired nasal/throat samples (r > 0.8, p < 0.001). Patients with high ARG carriage in both sample types were significantly more likely to report hospital visits for exacerbations or bacterial infections (90% within three months). Resistance determinants to macrolides, tetracyclines, aminoglycosides, β-lactams, and sulfonamides predominated, with 27 ARGs detected in at least half of the cohort. Clinically important genes, including blaNDM-1, mcr-1, mecA, and vanA, were present in 67–70% of samples, revealing a diverse and concerning genetic landscape. Poor cleaning, improper storage, and recent antibiotic use were independently associated with higher ARG abundance (r > 0.7, p < 0.001).
This study provides the first evidence that inhalers function as clinically relevant reservoirs of ARGs, closely reflecting the respiratory tract resistome and linking device contamination with adverse clinical outcomes. These findings uncover a previously unrecognized pathway for AMR persistence and transmission, underscoring the urgent need for improved inhaler hygiene, patient education, and targeted infection-prevention strategies, particularly in low- and middle-income countries.